 Newly diagnosed multiple myeloma participants receiving induction chemotherapy will be continuously bio-monitored at baseline 1-7 days prior to treatment initiation and during induction chemotherapy up to completion of 6 cycles using the Garmin Vivofit wearable device. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT. The study will include a total of 40 newly diagnosed multiple myeloma participants in two cohorts with 20 patients in each cohort Cohort A and B. Cohort A will be comprised of patients 65 years. Cohort B will be comprised of patients 65 years. 